Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities

Immune checkpoint inhibitors (ICIs) are newly approved treatments for advanced malignancies that are increasing survival. The mechanism of these drugs, non-specifically activating T cells, also leads to immune-mediated damage of tissue or immune-related adverse events (IRAE). IRAEs with rheumatic ph...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:RMD Open
Main Authors: Cappelli, Laura C, Shah, Ami A, Bingham, Clifton O
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2016
Assuntos:
Autoimmunity
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5051426/
https://ncbi.nlm.nih.gov/pubmed/27752360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2016-000321
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados